EMA Authorised: Vanflyta (quizartinib dihydrochloride) — Daiichi Sankyo Europe GmbH

View source ↗

Summary

Vanflyta (quizartinib dihydrochloride) has been authorised in Europe for leukemia/myeloid indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myeloid Leukemia

Drugs mentioned

• VANFLYTA (quizartinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid. MAH: Daiichi Sankyo Europe GmbH. Decision date: 09/07/2026